TScan Therapeutics, Inc. (TCRX) - Long-Term Debt to Capital

TScan Therapeutics brings together leading T-cell therapy specialists, incentivizing scientific research through bonuses. Developments are based on a proprietary target identification ecosystem, which binds pharma behemoths via licenses. The ratio of long-term debt to equity shows that this metric equals 1.12. Currently, fixed R&D costs and the pre-profit stage are constraining the overall business margins.

Investors must balance the growth potential of shares with the issuer's debt sustainability. This long-term debt-to-equity ratio measures the proportion of borrowed funds with a maturity exceeding one year relative to equity. The declining values on this chart indicate increasing financial autonomy. For TScan Therapeutics (TCRX), low leverage is critically important when financing the high-tech development of the TargetScan platform, ensuring the security of investments in creating precision therapies for solid tumors.